This post is from a suggested group
The Future Trajectory of Cancer Care: Analyzing the Dominance of Targeted Therapies in the Generic Oncology Drug Market Segment
Description Section While conventional chemotherapy has long been the backbone of cancer treatment, targeted therapy drugs, which interfere with specific molecules needed for tumor growth, are now defining the future of oncology. This shift is also evident in the generic sector, where targeted therapies are gaining significant market traction. Targeted drugs are either the largest or fastest-growing segment in the overall oncology market, and their generic counterparts are mirroring this trend. This dominance is due to their precision, which results in better patient tolerance and outcomes compared to traditional cytotoxic chemotherapy. As patents for more targeted drugs—such as tyrosine kinase inhibitors and monoclonal antibodies—expire, the introduction of generic and biosimilar versions will democratize access to these advanced treatments. Forecasts suggest the targeted therapy segment could reach over $16 billion by 2032.
The…